Improving quality of life after breast cancer: Prevention of other diseases

Menopause International

Volumn 13, Issue 2, 2007, Pages 71-74

  Rozenberg, Serge ^a   Antoine, Caroline ^a   Carly, Birgit ^a   Pastijn, Ann ^a   Liebens, Fabienne ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

BREAST CANCER; CANCER; CARDIOVASCULAR DISEASE; OSTEOPOROSIS; SURVIVAL

Indexed keywords

ALKYLATING AGENT; ANASTROZOLE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CYCLOPHOSPHAMIDE; DOXORUBICIN; EXEMESTANE; GONADORELIN AGONIST; GONADORELIN DERIVATIVE; LETROZOLE; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB; VITAMIN D;

ADJUVANT THERAPY; AMENORRHEA; BONE METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CANCER SURVIVOR; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COLORECTAL CANCER; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG MEGADOSE; EARLY CANCER; EARLY DIAGNOSIS; ENDOMETRIUM CANCER; FEMALE; FRACTURE; FRAGILITY FRACTURE; HEALTH PROGRAM; HUMAN; ISCHEMIC HEART DISEASE; LUNG CANCER; MASTECTOMY; MORTALITY; MYELODYSPLASTIC SYNDROME; OSTEOLYSIS; OSTEOPOROSIS; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; SIDE EFFECT; STOMACH CANCER; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM; BREAST TUMOR; COLORECTAL TUMOR; EPIDEMIOLOGY; LUNG TUMOR; STATISTICS; STOMACH TUMOR; SURVIVOR; WOMEN'S HEALTH;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; CAUSALITY; COLORECTAL NEOPLASMS; COMORBIDITY; FEMALE; HUMANS; LUNG NEOPLASMS; OSTEOPOROSIS; QUALITY OF LIFE; STOMACH NEOPLASMS; SURVIVORS; TAMOXIFEN; THROMBOEMBOLISM; WOMEN'S HEALTH;

EID: 36048951466     PISSN: 17540453     EISSN: None     Source Type: Journal    
DOI: 10.1258/175404507780796398     Document Type: Review

References (23)

1. Nelson HD, Huffman LH, Fu R, Harris EL; U.S. Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 2005;143:362–79.
2. Liebens FP, Carly B, Pastijn A, Rozenberg S. Management of BRCA1/2 associated breast cancer: a systematic qualitative review of the state of knowledge in 2006. Eur J Cancer 2007;43: 238–57.
3. Davis VJ. Female gamete preservation. Cancer 2006;107 (Suppl 7):1690–4.
4. Oktay K, Sonmezer M. Ovarian tissue banking for cancer patients: fertility preservation, not just ovarian cryopreservation. Hum Reprod 2004;19:477–80.
5. Satariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 1994;120:104–10.
6. Rozenberg S, Ham H, Liebens F. Screening mammography in elderly women. Research on Breast Cancer in Older Women Consortium. JAMA 2000;283:3203.
7. Zhang Y, Kiel DP, Kreger BE, et al. Bone mass and the risk of breast cancer among postmenopausal women. N Engl J Med 1997;336:611–17.
8. Kanis JA, McCloskey EV, Powles T, et al. A high incidence of vertebral fracture in women with breast cancer. Br J Cancer 1999; 79:1179–81.
9. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005;97:1652–62.
10. Fogelman I, Blake GM, Blamey R, et al. Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Osteoporos Int 2003;14:1001–6.
11. Thurlimann B, Keshaviah A, Coates AS, et al.; Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747–57.
12. McCloskey EV. Effects of third-generation aromatase inhibitors on bone. Eur J Cancer 2006;42:1044–51.
13. Body JJ, Bergmann P, Boonen S, et al. Management of cancer treatment-induced bone loss in early breast and prostate cancer: a consensus of the Belgian Bone Club. Osteoporosis Int (submitted).
14. Paterson AH. Evaluating bone mass and bone quality in patients with breast cancer. Clin Breast Cancer 2005;5 (Suppl 2):S41–5.
15. Mellemkjaer L, Friis S, Olsen JH, et al. Risk of second cancer among women with breast cancer. Int J Cancer 2006;118:2285–92.
16. Galper S, Gelman R, Recht A, et al. Second nonbreast malignancies after conservative surgery and radiation therapy for early-stage breast cancer. Int J Radiat Oncol Biol Phys 2002;52: 406–14.
17. Kmet LM, Cook LS, Weiss NS, Schwartz SM, White E. Risk factors for colorectal cancer following breast cancer. Breast Cancer Res Treat 2003;79:143–7.
18. Burstein HJ, Winer EP. Primary care for survivors of breast cancer. N Engl J Med 2000;343:1086–94.
19. Tan-Chiu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23:7811–19.
20. Hojris I, Overgaard M, Christensen JJ, Overgaard J. Morbidity and mortality of ischaemic heart disease in high-risk breastcancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: analysis of DBCG 82b and 82c randomised trials. Radiotherapy Committee of the Danish Breast Cancer Cooperative Group. Lancet 1999;354: 1425–30.
21. Hooning MJ, Aleman BM, van Rosmalen AJ, et al. Cause-specific mortality in long-term survivors of breast cancer: a 25-year follow-up study. Int J Radiat Oncol Biol Phys 2006;64:1081–91.
22. Nordenskjold B, Rosell J, Rutqvist LE, et al. Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: results from a randomized trial. J Natl Cancer Inst 2005;97:1609–10.
23. Nabholtz JM, Gligorov J. Cardiovascular safety profiles of aromatase inhibitors: a comparative review. Drug Saf 2006;29: 785–801.